Stock listing

IKT Stock Price, News, Filings & Events — Inhibikase Therapeutics, Inc.

Selected listing: IKT · NASDAQ · USD · US

This page tracks Inhibikase Therapeutics, Inc.'s IKT:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IKT:NASDAQ. IKT:NASDAQ is the stock-level entry point for investors researching Inhibikase Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Inhibikase Therapeutics, Inc. is a public company traded under the ticker IKT in the American market. The company has a market capitalization of approximately $307.6 million. Inhibikase is focused on developing innovative therapies for neurodegenerative diseases.

IKT:NASDAQUSDUSUpdated September 11, 2026
Inhibikase Therapeutics, Inc. logo
Ticker
IKT:NASDAQ
Asset type
Stock
Market cap
$326.5M
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
NASDAQ
Currency
USD

Inhibikase Therapeutics, Inc. IKT:NASDAQ stock context

This page tracks Inhibikase Therapeutics, Inc.'s IKT:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IKT:NASDAQ. IKT:NASDAQ is the stock-level entry point for investors researching Inhibikase Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Inhibikase Therapeutics, Inc. is a public company traded under the ticker IKT in the American market. The company has a market capitalization of approximately $307.6 million. Inhibikase is focused on developing innovative therapies for neurodegenerative diseases.

Latest news from Inhibikase Therapeutics, Inc.

All Inhibikase Therapeutics, Inc. news →

Inhibikase Therapeutics, Inc. earnings calls

Research Inhibikase Therapeutics, Inc.

Alternate listings